Lopez Navarro Omar G, Cervera-Ceballos Eduardo E, Poitevin-Chacón Adela, Perez-Lopez Hidralba, Flores-Vazquez Fabiola, Urbalejo-Ceniceros Víctor I, Arriaga-Marroquin Jose A, Aviles-Salas Alejandro, Sanchez-Rodriguez Irving E, Villalvazo Alejandro, Gutierrez-Valencia Enrique, Gonzalez-Espinosa Tomas F
Hematology and Medical Oncology, Medica Sur, Mexico City, MEX.
Hematology, Instituto Nacional de Cancerología, Mexico City, MEX.
Cureus. 2025 Jul 27;17(7):e88864. doi: 10.7759/cureus.88864. eCollection 2025 Jul.
Rosai-Dorfman disease (RDD) is a rare subtype of sinus histiocytosis, with primary cutaneous RDD (PCRDD) being an even rarer form, characterized by cutaneous lesions without systemic involvement. PCRDD presents a significant diagnostic challenge and is often resistant to conventional therapies, including surgical resection, steroids, and chemotherapy. Currently, no established management guidelines exist for this condition. Radiation therapy is emerging as a promising treatment option, especially for refractory cases involving cosmetically sensitive or difficult-to-resect areas. This case report presents a patient with treatment-resistant PCRDD affecting the face, which was refractory to multiple therapeutic approaches, including chemotherapy. The patient achieved durable remission with radiation therapy at an 18-month follow-up, highlighting the efficacy of this modality in managing resistant PCRDD and the importance of a multidisciplinary approach.
罗萨伊-多夫曼病（RDD）是鼻窦组织细胞增多症的一种罕见亚型，原发性皮肤罗萨伊-多夫曼病（PCRDD）则更为罕见，其特征为皮肤病变且无全身受累。PCRDD带来了重大的诊断挑战，并且通常对包括手术切除、类固醇和化疗在内的传统疗法耐药。目前，针对这种病症尚无既定的管理指南。放射治疗正成为一种有前景的治疗选择，尤其是对于涉及美容敏感或难以切除区域的难治性病例。本病例报告介绍了一名患有面部难治性PCRDD的患者，该患者对包括化疗在内的多种治疗方法均无效。在18个月的随访中，患者通过放射治疗实现了持久缓解，突出了这种治疗方式在管理耐药性PCRDD方面的疗效以及多学科方法的重要性。
